联邦制药(03933)：UBT251 注射液获美国 FDA 新药临床试验批准
联邦制药(03933)公布，于2023年9月26日，由公司全资附属公司联邦生物科技(珠海横琴)有限公司自主研发的 1 类创新药 UBT251 注射液关于成人 2 型糖尿病、超重或肥胖适应症的新药临床试验申请(IND)获美国食品药品监督管理局(FDA)批准，IND 编号为 167739 和 167740。
据悉，UBT251 是一款由该公司自主研发的 GLP-1(胰高血糖素样肽-1)/GIP(葡萄糖依赖性促胰岛素多肽)/GCG(胰高血糖素)三靶点受体激动剂。公司是中国首家、全球第二家以化学合成多肽法制备的长效 GLP-1/GIP/GCG 三激动剂获准临床的企业，目前已取得中国及美国两地药物临床试验批准。
Reprinted from 引领外汇网，the copyright all reserved by the original author.
Disclaimer: The content above represents only the views of the author or guest. It does not represent any views or positions of FOLLOWME and does not mean that FOLLOWME agrees with its statement or description, nor does it constitute any investment advice. For all actions taken by visitors based on information provided by the FOLLOWME community, the community does not assume any form of liability unless otherwise expressly promised in writing.
FOLLOWME Trading Community Website: https://www.followme.com
Hot
No comment on record. Start new comment.